⌘K

Login Start Free

Home/Filings/4/0001225208-15-010603

4//SEC Filing

Merck & Co., Inc. 4

Accession 0001225208-15-010603

$MRKCIK 0000310158operating

View on SEC.gov Company Profile

Filed

Apr 28, 8:00 PM ET

Accepted

Apr 29, 6:01 PM ET

Size

14.2 KB

Accession

0001225208-15-010603

Insider Transaction Report

Form 4

Period: 2015-04-29

Merck & Co., Inc.MRK

Exec. V.P. and General Counsel

Transactions

Sale
Common Stock
2015-04-29$59.58/sh−65,306$3,890,886→ 236,391.143 total
Sale
Common Stock
2015-04-29$60.00/sh−91,596$5,495,760→ 144,795.143 total
Exercise/Conversion
Common Stock
2015-04-29$36.56/sh+44,776$1,637,011→ 301,697.143 total
Exercise/Conversion
Stock Option (right to buy)
2015-04-29−112,126→ 56,064 total
Exercise: $39.29From: 2013-05-02Exp: 2022-05-01→ Common Stock (112,126 underlying)
Exercise/Conversion
Common Stock
2015-04-29$39.29/sh+112,126$4,405,431→ 256,921.143 total
Exercise/Conversion
Stock Option (right to buy)
2015-04-29−44,776→ 0 total
Exercise: $36.56From: 2012-05-04Exp: 2021-05-03→ Common Stock (44,776 underlying)

Footnotes (5)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.2600 to $59.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.8600 to $60.4100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F3]Holdings include shares acquired in dividend reinvestment transactions.
[F4]The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
[F5]The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014.

Documents

1 file

4
doc4.xmlPrimary

Issuer

Merck & Co., Inc.

CIK 0000310158

Entity typeoperating

IncorporatedNJ

Related Parties

1

filerCIK 0000310158

Filing Metadata

Form type: 4
Filed: Apr 28, 8:00 PM ET
Accepted: Apr 29, 6:01 PM ET
Size: 14.2 KB

View on SEC.gov